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INTRODUCTION 
In many clinical specialties including neurology, 
cardiology and orthopedics, implantable medical devices 
are frequently used. Devices like joint replacements, pain 
pumps and pacemakers perform an fludic, mechanical, or 
electronic function to lead patients to perform their normal 
body functions. To reduce morbidity and improve efficacy, 
many manufacturers of device have integrated chemicals 
or drugs into medical implants in the past decade. For 
instance when comparing the Drug-eluting stents with bare 
metal stents it was found that drug eluting stent reduce in-
stent restenosis.1   Patient compliance is a major problem 
where frequent dose administration is required, in these 
cases a health professionals are in dare need to have an 
automated drug delivery system.  
A drug delivery system can be defined as mechanism to 
introduce therapeutic agent into the body.  Drug delivery 
systems have had a high impact on technology, greatly 
enhance the presentation of many current drugs & 
facilitate the use of new therapies.2 Santini el al., first 
developed one class of combination products featuring on-
demand drug release capabilities that was a microchip with 
many reservoirs containing discrete doses of drug .3-5  
Micro-electronic devices have become essential part of 
today‟s life. They are present in our cellular phones, 
computers and automobiles.6 Technology enable to 
develop revolutionary opportunities in every field of life 
and this stimulated the development of innovative 
techniques in drug delivery system. Recent advances in the 
field of drug delivery system created the possibility to 
meet the patient need. For this a new drug delivery system 
is design that is wireless control drug delivery system that 
work through “microchip”.7  
 Need of wireless drug delivery system 
Wireless drug delivery system has the capability to 
improve patient compliance as patient compliance is a 
major issue, especially in chronic diseases. Such issues 
include „simply forgetting, that is 65%; „concerns about 
the drugs‟ that is 45%; and feeling the „drug is 
unnecessary‟ is  43%, it is just because of long term use 
and complex drug regimen.8 Traditionally, research has 
concentrated on recognizing why patients are non-
compliant and the strategies to increase compliance.9  
The pattern of treatment has been changed drastically after 
the emergence of programmable chips for chronic ailments 
patients like cancer, multiple sclerosis and osteoporosis. In 
conditions where frequent daily injections are needed 
mostly in case of chronic illnesses where regular pain 
management is required, can have benefits from this 
technology, 9 
 
Therefore, if a drug delivery device is capable of being 
controlled from outside the body and can release many 
types of drugs continuously and also implantable safely in 
human body, will be greatly advantageous. Many factors 
that must be come into account for manufacturing of 
effective and successful drug delivery system few includes 
how it is being processed, reliability of material, 
biocompatibility and drug release pattern.10  
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Microchips 
Microchips are smart medical implants that can dispense 
drugs into the bloodstream by getting wireless signals sent 
to them from the medical implant communication service 
(MICS).11  Localized delivery, delivery on demand, 
controlled drug release, dose checking and physician 
option to remotely adjust treatment schedule are 
advantages of these chips.12 Implantable medical device is 
not a new term; such devices are in use such as pace-maker 
and pain pumps.13 This smart implant can be injected 
under the skin in the doctor's office in about 30 minutes 
using a local anesthetic and lasts about four months before 
needing to be replaced.14  
How it works  
Microchip based implants are programmed to release drugs 
inside the body through wireless system. This contains 
micro reservoir where drug is stored and it is sealed with 
platinum and titanium membrane.  This is planted in 
human body under the skin and when the drug release is 
needed, the device is activated through wireless signal and 
an electrical current is applied which melt the membrane 
and release the drug inside the body. When drug reservoir 
is empty, the next dose can be delivered through another 
reservoir.15
  
 
 
Figure 1: Working of Microchip for wireless drug delivery system (source:www.mchips.com) 
CLINICAL TRIALS 
Microchip based drug delivery device trial was first 
performed clinically in eight osteoporotic postmenopausal 
women where the discrete doses of lyophilized hPTH(1–
34) containing devices were implanted. The dose has been 
released once daily through wireless controlled drug 
delivery system for 20 days. The hPTH(1–34) was 
analyzed for bioequivalence, safety, tolerability and 
pharmacokinetics. It is revealed that release of drug from 
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device on daily basis increased bone formation. No 
adverse effect or toxicity seen and device did not affect 
quality of life.16 
Application of WDDS in Osteoporosis: 
Osteoporosis is treated by Human parathyroid hormone 
fragment (1–34) [hPTH(1–34)]. It occurs if the balance of 
bone resorption and formation process disturbed. In 
osteoporosis bone mineral density is lost which causes 
bone fractures. According to World Health Organization 
about 9 million fractures per year in the world are due to 
osteoporosis, and contribute significantly to disability 
rates. 17 The projected cost of these fractures in US is 
estimated as more than $20 billion .18 The drugs used to 
treat osteoporosis are classified in two classes, one type is 
bone resorption inhibitors that include calcitonin, 
bisphosphonates, and estrogens,  , and the second type are 
anabolic agents, such as human parathyroid hormone 
[hPTH(1–84)] and teriparatide [hPTH(1–34)]. FDA given 
approval for  Eli Lilly and Company‟s teriparatide (U.S. 
and European Union trade names FORTEO and 
FORSTEO, respectively) in 2002. The Teripartide contains 
hPTH(1–34) as the active agent. It is indicated for 
osteoporosis treatment in both who are at fracture risk. The 
estimated number of teriparatide users in the United States 
in 2010 were 50, 000.19 Regular hPTH(1–34) 
administration encourage osteoclast activity, which casue 
bone loss.20, 21 On the other hand, intermittent or pulsatile 
delivery of hPTH(1–34) is used as anabolic therapy and 
incite osteoblast activity (bone formation) greater than 
osteoclast  activity,  and  so the bone mineral density and 
mass increased.22 Daily administration of 20- to 40-mg 
doses of hPTH (1–34) through subcutaneous route for 
around 2 years cause a decrease in fracture incidence and it 
is with acceptable profile of safety.23, 24 But the patient 
compliance for daily subcutaneous injections is poor. 25 
The first candidate which was selected for human trial was  
hPTH(1–34). The  programmable implant was used in 
clinical trials that deliver hPTH(1–34) at scheduled 
intervals, with a similar PK value as in case of daily 
subcutaneous injections.16 
 
Figure 2: Microchip used in human trial 
(source:www.mchips.com & R.Farra et al., 2012) 
CHALLENGES AND OPPORTUNITIES 
Although the microchips based wireless drug delivery 
system seems to be perfect for patients with chronic 
ailments but there are some problems in the commercial 
development of these devices that includes:  
 complexity (as multiple system interaction is required, 
and failure risk is higher),  
 cost is high 
 potentially harmful (a minor surgery is needed) 
 obtrusive  (existing device has a large size) and  
 Limitation in drug loading (only few drugs are 
feasible to be loaded for a long therapy). Like every 
other technology, these factors will have to be 
eliminated and the factors for success of this 
technology will be:  
 validated proof that technology is feasible,  
 an approval from regulatory body  
 more stress advanced new delivery systems  
 capability to meet important  medical requirement  
 
SUBJECTS AND METHOD:  
A brief awareness to the WDDS has been given to the 
patients and then the study was performed. A questionnaire 
has been prepared after reviewing literature in view of 
objective of study based quantitative approach. The data 
has been collected from patients at random who are under 
treatment at primary, secondary and tertiary health care 
units by a cross sectional study among three different 
categories of participants those might be the main 
stakeholder for future use of WDDS. Study design of data 
collection is shown in Figure 3.  
A total of 267 patients were approached out of which 203 
were agreed participated in the survey. For each category 
of participants 50 were randomly selected to fill 
questionnaire forms for data collection and compilation.  
 
 
Figure 3:   Study Design for data collection 
 QUESTIONNAIRE LAYOUT: 
The participants were required to fill a structured 
questionnaire comprising of 20 questions. It covered all 
aspects of Wireless Drug delivery system (WDDS) and its 
future use in the patients with chronic illnesses In addition 
to these questions, personal profile of patients such as 
name, age group, occupation was asked. Name and 
occupation declaration was optional because it may cause 
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reluctance to give actual information. An additional space 
was provided for comment and feedback.  
INFORMED CONSENT: 
The objective of this survey was explained after giving a 
brief introduction to WDDS and verbal consent was 
obtained from the patients. It was also informed that the 
data will be used for survey purpose only. Most of the 
participant filled the questionnaire on their own and few 
were interviewed as well to assist them in filling the 
questionnaire.
 
Table 1: Patient Response after brief awareness on WDDS 
 
S.NO STATEMENT Osteoporosis 
patients 
Diabetic 
Patients 
Other 
Chronic 
Patients 
1 Patients agreeing that new technology development can make their lives 
comfortable. 
87% 92% 81% 
2 Patients who can rely on new development in the field of drug delivery 
after trials in the western world. 
62% 79.00% 56.00% 
3 Patients who think that the surgical procedure will be better option for 
medication intake. 
45% 56.00% 63.00% 
4 Patients have consent if a minor surgery can make it avoidable for a 
year of medication intake through injections. 
78% 86% 81.00% 
5 Patients who think that wireless system will work properly and it will 
not be with any technical problem such as battery, weak signals etc. 
35% 47.00% 50% 
6 Patients have a blind-faith on physician advice for new WDDS. 55.00% 54.00% 51.00% 
 
RESULTS: 
A total of 203 patients were responded to participate in the 
survey out of 267 approached patients (response factor was 
76 %). The samples were selected in such a way that from 
each category 50 participants filled the questionnaire and 
responses were recorded. The results showed that greater 
percentage of participants agreed that new technological 
advancement is making their life easier and comfortable. 
About 87 % of the patients think that this statement is 
right. 65% of participant think that new advancement in 
the field of drug development will be beneficial for them 
among those highest positive thinkers were diabetic 
patients.   
 
Figure 4: Confidence level of chronic ailment patients 
on technological advancement in Karachi, Pakistan 
A half of the participants believe that surgical procedure 
can be a better option for medication intake. Patients who 
think that minor surgery is a better option to take a 
medicine instead of taking medication for years through 
injection was about 82 %. More than 50 % patients have 
the idea that this system will be with technical problems. 
DISCUSSION: 
The survey revealed that most of the chronic ailment 
patients in Karachi, Pakistan will response in affirmative 
for the adaptability of new technology. But the % of 
adaptability may be lesser for WDDS as compare to new 
technology like cell phone or any other new technology. 
This may be because of the fact the people are reluctant to 
take risk for health management except where they have 
solid data or if they say someone by themselves who have 
benefited with the technology. There might be the reason 
involve that the new technology may be with some side 
effects or with some other technical issue to use them. The 
technical issue may be battery, or weaker signals of device 
that may cause hindrance in the use of WDDS.  
For the purpose of ease in taking medication, overall they 
prefer to go through a minor surgery instead of taking 
daily injections. A surprising but good thing which has 
been revealed that for the matter of adapting this new 
technology they will not blindly trust on their physician 
but it will the case of acceptability only if they have strong 
data and/or observed someone used it personally. It has 
two possible options either they are not eager to take risk 
or they want to have knowledge by themselves.
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CONCLUSION:  
The union of drug delivery and electronic technologies 
provides physicians a better link with the health of  
patient.7 Technical success is a precondition but does not 
guarantee commercial success.  New drug delivery system 
development are always with successes and failures so it is 
unrealistic to predict about the innovative product future.  
Chronic Patient in Karachi, Pakistan may adopt the 
technology and over all a positive response will be there if 
the technology will come to them with strong data, lesser 
side effect and easy use. 
It seems to have an innovative discovery for mankind 
which has pharmacy on a chip, enhancing patient 
compliance. In the end, WDDS provides a new treatment 
option for physician where effectiveness of conventional 
dosing methods is inconvenient when estimated on the 
parameter of pain, efficacy and safety. WDDS minimize 
the compliance problem and leads to a future where you 
have fully automated drug regimens. 
FUTURE PROSPECTS: According to the Robert Ferra, 
the data obtained through studies validate the microchip 
approach to multi-year drug delivery without the need for 
daily injections, can improve can improve many chronic 
diseases like osteoporosis management. They are also 
planning to develop products for use in important disease, 
multiple sclerosis, cancer and chronic pain 
MicroCHIPS is working on microchip-based implant that 
may include as many as 400 doses in a device for less 
frequent dosing regimens. It is expected that MicroCHIPS 
will file an application regulatory approval of first 
microchip device in 2014.26 
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